Compare AbCellera Biologics Inc (ABCL) vs Vistra Corp (VST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Vistra Corp — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Vistra Corp trades at $154.85 (market cap $52.51B). The key difference: Vistra Corp is far larger — about 22.3× AbCellera Biologics Inc's market cap, and Vistra Corp pays a 0.59% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | VST | |
|---|---|---|
Market Cap | $2.35B | $52.51B |
Sector | Health | Technology |
52-Week High | $8.12 | $217.92 |
52-Week Low | $2.78 | $134.71 |
Enterprise Value | $1.99B | $74.26B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Vistra Corp (VST) trades at $157.22, up 4.08% with a bearish technical signal despite strong analyst support. The stock shows mixed earnings performance with recent beats but faces cash flow challenges. Revenue growth from $17.74B to $19.4B and improved net margins to 11.52% reflect operational strength, supported by AI-driven power demand catalysts and a $6.3B buyback program.
Outlook remains positive with 91% analyst buy ratings and a $230.50 price target, though technical resistance near $159 and volatile earnings pose near-term risks. Long-term growth is fueled by nuclear/renewable expansion, but investors should monitor execution on guidance and energy market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
